Company profile
Apmonia Therapeutics
Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies.
- Industry
- Biotechnology
- Employees
- 20
- Headquarters
- Reims, Grand Est
- Founded
- 2019
- LinkedIn followers
- 4,330
- Office locations
- 1
Apmonia Therapeutics company summary
Apmonia Therapeutics is a company in the Biotechnology industry, headquartered in Reims, Grand Est, founded in 2019. On LinkedIn the company has around 20 employees and 4,330 followers. Its listed specialties include immunologie and oncologie.
What technology does Apmonia Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Apmonia Therapeutics
Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors.
Specialties
Where is Apmonia Therapeutics located?
Apmonia Therapeutics lists 1 location.
Compare companies similar to Apmonia Therapeutics
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Apmonia Therapeutics apmonia-therapeutics.com | Biotechnology | 20 | 2019 | Reims, Grand Est |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Apmonia Therapeutics
What does Apmonia Therapeutics do?
Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors.
How many employees does Apmonia Therapeutics have?
Apmonia Therapeutics has around 20 employees on LinkedIn.
Where is Apmonia Therapeutics headquartered?
Apmonia Therapeutics is headquartered in Reims, Grand Est.
When was Apmonia Therapeutics founded?
Apmonia Therapeutics was founded in 2019.
Build a lead list from companies like Apmonia Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.